adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Schizophrenia · Alzheimer's Disease Psychosis · ACAD
Acadia Pharmaceuticals
Acadia Pharmaceuticals B.V.
Acadia Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Indianapolis, USA HQ
17 Employees
Public company Type
ACAD · NYSE Ticker
Company details
- Status
- Public
- HQ
- Indianapolis, USA
- Employees
- 17
- Programs
- 4
- Drugs
- 6
- Patents
- 16
Acadia Pharmaceuticals pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Acadia Pharmaceuticals drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Acadia Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Acadia Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
- Target
- 5-hydroxytryptamine receptor 2A
- Mechanism
- Serotonin 2a (5-HT2a) receptor inverse agonist
-
trofinetide
Nervous system (N07)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown